The increase in the number of infiltrating CD4 and CD8 cells in the TME after anti-PD1 immunotherapy may be one of the mechanisms by which immunotherapy works in ccRCC. The gene discussed is CD8A; the disease is nonpapillary renal cell carcinoma.